The Centers for Disease Control and Prevention states that individuals with diabetes are at higher risk for severe illness with coronavirus disease 2019 (COVID-19) and poorer health outcomes ([@B1]). Research suggests the underlying reason for an increased risk of COVID-19 complications in individuals with diabetes may be poor glycemic control or hyperglycemia ([@B2]). Information on clinical outcomes for patients with type 1 diabetes who have confirmed cases of COVID-19 is limited. To our knowledge, this is the first U.S.-based multicenter study that addresses these questions in a population with type 1 diabetes.

This study aimed to examine patient characteristics and adverse outcomes among patients with type 1 diabetes with confirmed COVID-19. As a secondary objective, we investigated patient attributes and clinical outcomes in people with COVID-19--like symptoms for whom testing was unavailable or results were pending.

The T1D Exchange Quality Improvement Collaborative (T1DX-QI) ([@B3]) is conducting this study in collaboration with an additional 49 endocrinology clinics (a total of 64 U.S. sites). The study was approved as exempt by a central review board (Western Institutional Review Board \[WIRB\]). Each clinic obtained approval locally as appropriate. In this study, clinics report deidentified data from their patients with type 1 diabetes who tested positive for COVID-19 as well as for patients with symptoms and a medical history consistent with COVID-19 illness.

In the registry, patients were classified as COVID-19 positive if they had tested positive for COVID-19 through a molecular test (RT-PCR) of samples collected from nasopharyngeal swabs, throat swabs, sputum, etc. ([@B1]).

Patients were classified as having COVID-19--like cases if they exhibited any of the most common COVID-19 symptom profiles as identified by the Centers for Disease Control and Prevention including fever, cough, shortness of breath, myalgia, runny nose, sore throat, headache, nausea or vomiting, abdominal pain, diarrhea, or any combination of these symptoms ([@B4]). Additionally, household exposures for COVID-19 were recorded for patients who presented with any of the above-listed symptoms.

Data were collected using a 33-item questionnaire via the Qualtrics survey tool (<https://t1dexchange.org/COVID19>). As of 5 May 2020, we described data available on 33 COVID-19--positive and 31 COVID-19--like patients with type 1 diabetes, reported from participating clinics within the U.S. ([Table 1](#T1){ref-type="table"}).

###### 

Preliminary data: patient characteristics, symptoms, and outcomes in the T1D COVID-19 study

  Patient attributes                                                  All patients (*N* = 64)   COVID-19--positive case group (*N* = 33)   COVID-19--like case group (*N* = 31)
  ------------------------------------------------------------------- ------------------------- ------------------------------------------ --------------------------------------
  Mean age in years (SD)                                              20.9 (14.84)              24.8 (17.49)                               16.8 (10.10)
  Age categories                                                                                                                           
   ≤18 years                                                          42 (65.6)                 17 (51.52)                                 25 (80.6)
   \>19 years                                                         22 (34.4)                 16 (48.5)                                  6 (19.4)
  Female sex                                                          39 (60.9)                 18 (54.5)                                  15 (48.3)
  Race/ethnicity                                                                                                                           
   Non-Hispanic white                                                 31 (48.4)                 12 (36.4)                                  19 (61.3)
   Non-Hispanic black                                                 12 (18.8)                 10 (30.3)                                  2 (6.5)
   Hispanic                                                           16 (25)                   7 (21.2)                                   9 (29.0)
   Asian/other/unknown                                                5 (7.8)                   4 (12.1)                                   1 (3.23)
  Education level (patient, or parent if patient \<18 years of age)                                                                        
   No high school                                                     8 (12.5)                  3 (9.1)                                    5 (16.1)
   High school graduate                                               12 (18.8)                 7 (21.2)                                   5 (16.1)
   College graduate or above                                          7 (10.9)                  6 (18.2)                                   1 (3.2)
   Unknown                                                            37 (57.8)                 17 (51.5)                                  20 (64.5)
  Insurance                                                                                                                                
   Private                                                            20 (31.3)                 9 (27.3)                                   11 (35.5)
   Public                                                             36 (56.3)                 23 (69.7)                                  13 (41.9)
  HbA~1c~ median, %                                                   8.0                       8.5                                        8.0
  Duration of type 1 diabetes                                                                                                              
   New onset                                                          6 (9.8)                   5 (15.6)                                   1 (3.4)
   \<1 year                                                           2 (3.1)                   ---                                        2 (6.9)
   1--2 years                                                         9 (14.8)                  2 (6.3)                                    7 (24.1)
   3--5 years                                                         15 (24.6)                 9 (28.1)                                   6 (20.7)
   6--10 years                                                        12 (19.7)                 4 (12.5)                                   8 (27.6)
   \>10 years                                                         17 (27.9)                 12 (37.5)                                  5 (17.2)
  CGM use (yes)                                                       32 (52.5)                 13 (40.6)                                  19 (65.5)
  Insulin pump use (yes)                                              27 (44.3)                 9 (28.1)                                   18 (62.1)
  Care managed remotely (yes)                                         37 (60.7)                 15 (46.9)                                  22 (75.9)
  Video/telemedicine as primary mode of remote care                   17 (46)                   8 (53.3)                                   9 (40.9)
  COVID-19 symptoms and medical care information                                                                                           
   Most prevalent symptoms                                                                                                                 
    High blood glucose                                                32 (50.8)                 16 (48.5)                                  16 (51.6)
    Elevated temperature                                              26 (41.3)                 15 (45.5)                                  11 (36.7)
    Dry cough                                                         24 (38.1)                 13 (39.4)                                  11 (36.7)
    Nausea                                                            19 (30.2)                 9 (27.3)                                   10 (33.3)
    Excess fatigue                                                    18 (28.6)                 11 (33.3)                                  7 (23.3)
    Body/headaches                                                    17 (27.0)                 7 (21.2)                                   10 (33.3)
    Shortness of breath                                               17 (27.0)                 10 (30.3)                                  7 (23.3)
    Vomiting                                                          16 (25.4)                 11 (33.3)                                  5 (16.7)
    Loss of taste                                                     7 (11.1)                  3 (9.1)                                    4 (13.3)
    Loss of smell                                                     6 (9.5)                   1 (3.0)                                    5 (16.7)
    Low blood glucose                                                 5 (7.9)                   1 (3.0)                                    5 (16.7)
    Loose stools                                                      5 (7.9)                   ---                                        5 (16.7)
   Most prevalent comorbidities                                                                                                            
    Obesity                                                           25 (39.7)                 13 (39.4)                                  12 (40)
    Hypertension/CVD                                                  9 (14.3)                  4 (12.1)                                   5 (16.7)
    Asthma                                                            5 (7.9)                   ---                                        5 (16.7)
    Hashimoto thyroiditis                                             7 (4.8)                   4 (12.1)                                   3 (10.0)
    Hyperlipidemia                                                    3 (4.8)                   1 (3.0)                                    2 (6.7)
   Smoking/vaping history                                                                                                                  
    Yes (current or previous)                                         6 (9.8)                   2 (6.3)                                    4 (13.8)
    No                                                                41 (64.1)                 20 (60.1)                                  21(67.7)
    Unknown                                                           15 (23.4)                 11 (32.3)                                  4 (12.9)
   Influenza vaccine this season                                                                                                           
    Yes                                                               26 (42.6)                 14 (43.8)                                  12 (41.4)
    No                                                                12 (18.8)                 3 (8.8)                                    9 (29.0)
    Unknown                                                           26 (40.6)                 16 (47.1)                                  10 (32.3)
   Highest level of care                                                                                                                   
    Intensive care unit                                               14 (22.2)                 10 (30.3)                                  4 (13.3)
    Inpatient or hospitalization                                      11 (17.5)                 9 (27.2)                                   2 (6.7)
    Emergency room                                                    5 (7.9)                   1 (3.0)                                    4 (13.3)
    Clinic or urgent care                                             8 (12.7)                  4 (12.1)                                   4 (13.3)
    At home                                                           22 (34.9)                 9 (27.3)                                   13 (43.3)
    Unknown                                                           3 (4.8)                   ---                                        3 (10.0)
   Adverse outcome                                                                                                                         
    Death                                                             2 (3.2)                   1 (3.0)                                    1 (3.3)
    DKA                                                               19 (30.2)                 15 (45.5)                                  4 (13.3)
    Severe hypoglycemia                                               3 (4.8)                   1 (3.0)                                    2 (6.7)
    Other                                                             6 (9.5)                   5 (15.2)                                   1 (3.3)
    None                                                              33 (52.4)                 13 (39.4)                                  20 (66.7)
    Unknown                                                           3 (4.8)                   1 (3.0)                                    2 (6.7)

Data are *n* (%) unless otherwise indicated. Data submitted to the registry as of 5 May 2020. CGM, continuous glucose monitoring; CVD, cardiovascular disease.

In the COVID-19--positive group (*N* = 33), 54.5% of patients were female and 36.4% were non-Hispanic white. The mean age was 24.8 years (SD 17.49, range 7.0--79.0). Median HbA~1c~ for all COVID-19--positive patients was 8.5%. The most prevalent presenting symptom reported was high blood glucose (48.5%), followed by elevated temperature (45.5%), dry cough (39.4%), excess fatigue (33.3%), vomiting (33.3%), shortness of breath (30.3%), nausea (27.3%), and body/headaches (21.2%). A smaller proportion (\<15%) of patients experienced chills, chest pain, loose stools, abdominal pain, loss of taste, and loss of smell.

The most prevalent comorbidity among patients with a confirmed case of COVID-19 was obesity (39.4%), followed by hypertension or cardiovascular disease (12.1%). The most prevalent adverse outcome within COVID-19--positive patients was diabetic ketoacidosis (DKA) (45.5%).

In the group that presented with COVID-19--like symptoms (*N* = 31), 48.3% of patients were female and 61.3% were non-Hispanic white. The mean age was 16.8 years (SD 10.1). Median HbA~1c~ was 8.0%. The most prevalent adverse outcome was DKA (13.3%). Most patients reported symptoms similar to those of patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including high blood glucose (51.6%), elevated temperature (36.7%), dry cough (36.7%), nausea (33.3%), body/headaches (33.3%), excess fatigue (23.3%), and shortness of breath (23.3%).

This preliminary report describes the most common presenting symptoms and outcomes for 64 people with type 1 diabetes who have confirmed or suspected COVID-19. More than 50% of all cases reported hyperglycemia, and nearly one-third of patients experienced DKA.

Future publications will address risk factors, provide regional insights, and describe associations and outcomes in pediatric and adult patients as more data are collected and analyzed.

This article is part of a special article collection available at <https://care.diabetesjournals.org/collection/diabetes-and-COVID19>.
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